Researchers describe how brain cells process antidepressants, cocaine and amphetamines. The findings could lead to more targeted medications for psychiatric diseases and addiction. (Sept. 17, 2008)
New York, NY (August 12, 2003) -- Physician-scientists at Weill Cornell Medical College and NewYork-Presbyterian Hospital have demonstrated that, among hypertensive patients with electrocardiographic evidence of a type of enlarged heart condition called left ventricular hypertrophy (LVH), the drug Losartan is more likely to reduce the severity of their condition than the drug Atenolol. Losartan's benefits were demonstrated throughout the five-year study period, irrespective of a number of factors, including the severity of the condition. LVH, a condition in which the heart's lower-left chamber (left ventricle) has grown thicker, is a risk factor associated with heart failure, myocardial infarction, and cardiovascular death.The study, published in the August 12 issue of Circulation, and available online, confirms earlier findings of the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension multicenter study of 9,193 hypertensive patients. The research shows that Losartan-based therapy was more effective at reducing LVH than the beta-blocker Atenolol, according to two electrocardiographic-based measurement standards: Sokolow-Lyon voltage and Cornell voltage-duration (Lancet 2002).
University Librarian Anne R. Kenney has won the American Library Association's Hugh C. Atkinson Award, which recognizes accomplishments in the areas of library automation or library management.
Cornell's first greenhouse gas inventory reveals that the university expects to reduce its central utilities emissions by almost one-third by 2010 -- far exceeding its goal of being 7 percent below 1990 carbon emission levels by 2012. (Sept. 16, 2008)
Dr. Alfonso Torres, deputy administrator for veterinary services at the U.S. Department of Agriculture Animal and Plant Health Inspection Service, has been named director of the New York State Animal Health Diagnostic Laboratory.
A reorganization announced July 1 by Cornell University President Hunter Rawlings and Provost Biddy Martin promises to streamline the structure of computing and information science instruction, tying the Department of Computer Science.
A head-cooling device called CoolCap prevents brain damage in some oxygen-deprived newborn babies, providing the first evidence in humans that many birth-related neurological problems can be reversed.
Susan Murphy ’73, Ph.D. ’94, vice president for student and academic services, delivered her "last lecture" at Cornell Dec. 3, focusing on the importance of gratitude.
NEW YORK (Feb. 2, 2005) -- The Center of Excellence for Lymphoma and Myeloma at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is the only medical center in the nation to currently offer a chemotherapy cocktail with the next-generation immuno-modulatory research drug Revlimid (lenalidomide), as part of a clinical trial for patients with newly diagnosed multiple myeloma. Results of the single-center Phase II clinical trial are anticipated to show improved complete remission rate and response time, and decreased toxicity -- compared to the standard treatment.